The role of lipocalins in airway disease

Clinical and Experimental Allergy

Volumn 43, Issue 5, 2013, Pages 503-511

  Dittrich, A M ^a   Meyer, H A ^b   Hamelmann, E ^c  

^a HANNOVER MEDICAL SCHOOL   (Germany)

^b CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^c RUHR UNIVERSITY BOCHUM   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

FATTY ACID BINDING PROTEIN; FATTY ACID BINDING PROTEIN 1; FATTY ACID BINDING PROTEIN 10; FATTY ACID BINDING PROTEIN 12; FATTY ACID BINDING PROTEIN 2; FATTY ACID BINDING PROTEIN 4; FATTY ACID BINDING PROTEIN 5; FATTY ACID BINDING PROTEIN 6; FATTY ACID BINDING PROTEIN 7; FATTY ACID BINDING PROTEIN 8; FATTY ACID BINDING PROTEIN 9; GAMMA INTERFERON; GELATINASE B; INTERLEUKIN 17; INTERLEUKIN 4; LIPOCALIN 1; NEUTROPHIL GELATINASE ASSOCIATED LIPOCALIN; PROSTAGLANDIN D SYNTHASE; RETINOL BINDING PROTEIN; RETINOL BINDING PROTEIN 1; RETINOL BINDING PROTEIN 2; RETINOL BINDING PROTEIN 4; RETINOL BINDING PROTEIN 5; TOLL LIKE RECEPTOR 4; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ACUTE RESPIRATORY FAILURE; BACILLUS ANTHRACIS; CHRONIC OBSTRUCTIVE LUNG DISEASE; COMPUTER ASSISTED TOMOGRAPHY; CYSTIC FIBROSIS; CYTOKINE PRODUCTION; DISEASE EXACERBATION; DISEASE SEVERITY; EMPHYSEMA; FIBROBLAST; FORCED EXPIRATORY VOLUME; HOST RESISTANCE; HUMAN; IN VIVO STUDY; LUNG ALVEOLUS MACROPHAGE; LUNG DYSPLASIA; LUNG LAVAGE; MORTALITY; NONHUMAN; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN BINDING; PROTEIN EXPRESSION; PROTEIN FUNCTION; PSEUDOMONAS INFECTION; RESPIRATORY TRACT ALLERGY; RESPIRATORY TRACT INFLAMMATION; REVIEW; SMOKING; SMOOTH MUSCLE CONTRACTION; VERY LOW BIRTH WEIGHT;

ANIMALS; HUMANS; HYPERSENSITIVITY; INFLAMMATION; LIPOCALINS; MULTIGENE FAMILY; RESPIRATORY TRACT DISEASES;

EID: 84876705020     PISSN: 09547894     EISSN: 13652222     Source Type: Journal    
DOI: 10.1111/cea.12025     Document Type: Review

References (82)

1. Pervaiz S, Brew K. Homology and structure-function correlations between alpha 1-acid glycoprotein and serum retinol-binding protein and its relatives. FASEB J 1987; 1:209-14.
2. Nagata A, Igarashi M, Toh H, Urade Y, Hayaishi O. Structural organization of the gene for prostaglandin D synthase in the rat brain. Proc Natl Acad Sci USA 1992; 89:5376-80.
3. Cowan SW, Jones TA, Newcomer ME. Crystallographic refinement of human serum retinol binding protein at 2A resolution. Proteins 1990; 8:44-61.
4. Flower DR, Attwood TK, North AC. Structure and sequence relationships in the lipocalins and related proteins. Protein Sci 1993; 2:753-61.
5. Godovac-Zimmermann J. The structural motif of beta-lactoglobulin and retinol-binding protein: a basic framework for binding and transport of small hydrophobic molecules? Trends Biochem Sci 1988; 13:64-6.
6. Lassagne H, Gachon AM. Exp Eye Res 1993; 56:605-9.
7. Redl B. Human tear lipocalin. Biochim Biophys Acta 2000; 1482:241-8.
8. Selsted ME, Martinez RJ. Isolation and purification of bactericides from human tears. Exp Eye Res 1982; 34:305-18.
9. Fluckinger M, Haas H, Merschak P, Glasgow BJ, Redl B. Human tear lipocalin exhibits antimicrobial activity by scavenging microbial siderophores. Antimicrob Agents Chemother 2004; 48:3367-72.
10. Lechner M, Wojnar P, Redl B. Human tear lipocalin acts as an oxidative-stress-induced scavenger of potentially harmful lipid peroxidation products in a cell culture system. Biochem J 2001; 356:129-35.
11. van't Hof W, Blankenvoorde MF, Veerman EC, Amerongen AV. The salivary lipocalin von Ebner's gland protein is a cysteine proteinase inhibitor. J Biol Chem 1997; 272:1837-41.
12. Nicholas BL, Skipp P, Barton S et al. Identification of lipocalin and apolipoprotein A1 as biomarkers of chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2010; 181:1049-60.
13. Jessie K, Pang WW, Haji Z, Rahim A, Hashim OH. Proteomic analysis of whole human saliva detects enhanced expression of interleukin-1 receptor antagonist, thioredoxin and lipocalin-1 in cigarette smokers compared to non-smokers. Int J Mol Sci 2010; 11:4488-505.
14. Lindahl M, Stahlbom B, Tagesson C. Newly identified proteins in human nasal and bronchoalveolar lavage fluids: potential biomedical and clinical applications. Electrophoresis 1999; 20:3670-6.
15. Redl B, Wojnar P, Ellemunter H, Feichtinger H. Identification of a lipocalin in mucosal glands of the human tracheobronchial tree and its enhanced secretion in cystic fibrosis. Lab Invest 1998; 78:1121-9.
16. Bundgaard JR, Sengeløv H, Borregaard N, Kjeldsen L. Molecular cloning and expression of a cDNA encoding NGAL: a lipocalin expressed in human neutrophils. Biochem Biophys Res Commun 1994; 202:1468-75.
17. Kjeldsen L, Cowland JB, Borregaard N. Human neutrophil gelatinase-associated lipocalin and homologous proteins in rat and mouse. Biochim Biophys Acta 2000; 1482:272-83.
18. Friedl A, Stoesz SP, Buckley P, Gould MN. Neutrophil gelatinase-associated lipocalin in normal and neoplastic human tissues. Cell type-specific pattern of expression. Histochem J 1999; 31:433-41.
19. Cowland JB, Sorensen OE, Sehested M, Borregaard N. Neutrophil gelatinase-associated lipocalin is up-regulated in human epithelial cells by IL-1 beta, but not by TNF-alpha. J Immunol 2003; 171:6630-9.
20. Meheus LA, Fransen LM, Raymackers JG et al. Identification by microsequencing of lipopolysaccharide-induced proteins secreted by mouse macrophages. J Immunol 1993; 151:1535-47.
21. Vizzardelli C, Pavelka N, Luchini A et al. Effects of dexamethazone on LPS-induced activationand migration of mouse dendritic cells revealed by a genome-wide transcriptional analysis. Eur J Immunol 2006; 36:1504-15.
22. Goetz DH, Holmes MA, Borregaard N, Bluhm ME, Raymond KN, Strong RK. The neutrophil lipocalin NGAL is a bacteriostatic agent that interferes with siderophore-mediated iron acquisition. Mol Cell 2002; 10:1033-43.
23. Holmes MA, Paulsene W, Jide X, Ratledge C, Strong RK. Siderocalin (Lcn 2) also binds carboxymycobactins, potentially defending against mycobacterial infections through iron sequestration. Structure 2005; 13:29-41.
24. Abergel RJ, Wilson MK, Arceneaux JE et al. Anthrax pathogen evades the mammalian immune system through stealth siderophore production. Proc Natl Acad Sci USA 2006; 103:18499-503.
25. Devireddy LR, Gazin C, Zhu X, Green MR. A cell-surface receptor for lipocalin 24p3 selectively mediates apoptosis and iron uptake. Cell 2005; 123:1293-305.
26. Mori K, Lee HT, Rapoport D et al. Endocytic delivery of lipocalin-siderophore-iron complex rescues the kidney from ischemia-reperfusion injury. J Clin Invest 2005; 115:610-21.
27. Flo TH, Smith KD, Sato S et al. Lipocalin 2 mediates an innate immune response to bacterial infection by sequestrating iron. Nature 2004; 432:917-21.
28. Saiga H. Lipocalin 2-dependent inhibition of mycobacterial growth in alveolar epithelium. J Immunol 2008; 181:8521-7.
29. Chan YR, Liu JS, Pociask DA et al. Lipocalin 2 is required for pulmonary host defense against Klebsiella infection. J Immunol 2009; 182:4947-56.
30. Wu H, Santoni-Rugiu E, Ralfkiaer E et al. Lipocalin 2 is protective against E. coli pneumonia. Respir Res 2010; 15:96.
31. Rodríguez N, Mages J, Dietrich H et al. MyD88-dependent changes in the pulmonary transcriptome after infection with Chlamydia pneumoniae. Physiol Genomics 2007; 30:134-45.
32. Dittrich AM, Krokowski M, Meyer HA et al. Lipocalin2 protects against airway inflammation and hyperresponsiveness in a murine model of allergic airway disease. Clin Exp Allergy 2010; 40:1689-700.
33. Sunil VR, Patel KJ, Nilsen-Hamilton M, Heck DE, Laskin JD, Laskin DL. Acute endotoxemia is associated with upregulation of lipocalin 24p3/Lcn2 in lung and liver. Exp Mol Pathol 2007; 83:177-87.
34. Karlsen JR, Borregaard N, Cowland JB. Induction of neutrophil gelatinase-associated lipocalin expression by co-stimulation with interleukin-17 and tumor necrosis factor-alpha is controlled by IkappaB-zeta but neither by C/EBP-beta nor C/EBP-delta. J Biol Chem 2010; 285:14088-100.
35. Nograles KE, Suárez-Fariñas M, Shemer A et al. Atopic dermatitis keratinocytes exhibit normal T(H)17 cytokine responses. J Allergy Clin Immunol 2010; 125:744-6.
36. Sevéus L, Amin K, Peterson CG, Roomans GM, Venge P. Human neutrophil lipocalin (HNL) is a specific granule constituent of the neutrophil granulocyte. Studies in bronchial and lung parenchymal tissue and peripheral blood cells. Histochem Cell Biol 1997; 107:423-32.
37. Schmekel B, Seveus L, Xu SY, Venge P. Human neutrophil lipocalin (HNL) and myeloperoxidase (MPO). Studies of lung lavage fluid and lung tissue. Respir Med 2000; 94:564-8.
38. Metso T, Rytilä P, Peterson C, Haahtela T. Granulocyte markers in induced sputum in patients with respiratory disorders and healthy persons obtained by two sputum-processing methods. Respir Med 2001; 95:48-55.
39. Ekberg-Jansson A, Andersson B, Bake B et al. Neutrophil-associated activation markers in healthy smokers relates to a fall in DL(CO) and to emphysematous changes on high resolution CT. Respir Med 2001; 95:363-73.
40. Keatings VM, Barnes PJ. Granulocyte activation markers in induced sputum: comparison between chronic obstructive pulmonary disease, asthma, and normal subjects. Am J Respir Crit Care Med 1997; 155:449-53.
41. Helenius IJ, Rytila P, Metso T, Haahtela T, Venge P, Tikkanen HO. Respiratory symptoms, bronchial responsiveness, and cellular characteristics of induced sputum in elite swimmers. Allergy 1998; 53:346-52.
42. Eagan TM, Damås JK, Ueland T et al. Neutrophil gelatinase-associated lipocalin: a biomarker in COPD. Chest 2010; 138:888-95.
43. Cundall M, Sun Y, Miranda C, Trudeau JB, Barnes S, Wenzel SE. Neutrophil-derived matrix metalloproteinase-9 is increased in severe asthma and poorly inhibited by glucocorticoids. J Allergy Clin Immunol 2003; 112:1064-71.
44. Eichler I, Nilsson M, Rath R, Enander I, Venge P, Koller DY. Human neutrophil lipocalin, a highly specific marker for acute exacerbation in cystic fibrosis. Eur Respir J 1999; 14:1145-9.
45. Dik WA, van Kaam AH, Dekker T et al. Early increased levels of matrix metalloproteinase-9 in neonates recovering from respiratory distress syndrome. Biol Neonate 2006; 89:6-14.
46. Dahlén I, Janson C, Björnsson E, Stålenheim G, Peterson CG, Venge P. Changes in inflammatory markers following treatment of acute exacerbations of obstructive pulmonary disease. Respir Med 2001; 95:891-7.
47. Sveger T, Ohlsson K, Mörse H, Polberger S, Laurin S. Plasma neutrophil lipocalin, elastase-alpha1-antitrypsin complex and neutrophil protease 4 in preterm infants with respiratory distress syndrome. Scand J Clin Lab Invest 2003; 63:89-92.
48. Devarajan P. Review: Neutrophil gelatinase-associated lipocalin: a troponin-like biomarker for human acute kidney injury. Nephrology 2010; 15:419-28.
49. Beuckmann CT, Lazarus M, Gerashchenko D et al. Cellular localization of lipocalin-type prostaglandin D synthase in the central nervous system of the adult rat. J Comp Neurol 2000; 428:62.
50. Kawashima M, Suzuki SO, Yamashima T, Fukui M, Iwaki T. Prostaglandin D synthase in meningeal hemangiopericytoma. Mod Pathol 2001; 14:197.
51. Ihizaka M, Ohe Y, Senbongi T, Wakabayashi K, Ishikawa K. Inflammatory stimuli increase prostaglandin D synthase levels in cerebrospinal fluid of rats. NeuroReport 2001; 12:1161.
52. Petereit HF, Bachmann G, Nekic M, Althaus H, Pukrop R. A new nephelometric assay for protein (prostaglandin D synthase) as an indicator of liquorrhoea. J Neurol Neurosurg Psychiatry 2001; 71:347.
53. Inoue T, Takayanagi K, Morooka S et al. Serum prostaglandin D synthase level after coronary angioplasty may predict occurrence of restenosis. Thromb Haemost 2001; 85:165.
54. Hirawa N, Uehara Y, Ikeda T et al. Urinary prostaglandin D synthase excretion increases in the early stage of diabetes mellitus. Nephron 2001; 87:321.
55. Berryhill BL, Beales MP, Hassell JR. Production of prostaglandin D synthase as a keratan sulfate proteoglycan by cultured bovine keratocytes. Invest Ophthalmol Vis Sci 2001; 42:1201.
56. Gerena RL, Eguchi N, Urade Y, Killian GJ. Stage and region-specific localization of lipocalin-type prostaglandin D synthase in the adult murine testis and epididymis. J Androl 2000; 2:848.
57. Eguchi Y, Eguchi N, Oda H et al. Expression of lipocalin-type prostaglandin D synthase (beta-trace) in human heart and its accumulation in the coronary circulation of angina patients. Proc Natl Acad Sci USA 1997; 94:14689-94.
58. 2 as a mediator of allergic asthma. Science 2000; 287:2013-7.
59. Hirai H, Tanaka K, Yoshie O et al. Prostaglandin D2 selectively induces chemotaxis in T helper type 2 cells, eosinophils, and basophils via seven-transmembrane receptor CRTH2. J Exp Med 2001; 193:255-61.
60. Ianaro A, Ialenti A, Maffia P, Pisano B, Di Rosa M. Role of cyclopentenone prostaglandins in rat carrageenin pleurisy. FEBS Lett 2001; 508:61-6.
61. 2 synthase suppresses lung injury induced by bleomycin. Am J Respir Cell Mol Biol 2003; 28:582-91.
62. Murakami Y, Akahoshi T, Hayashi I et al. Inhibition of monosodium urate monohydrate crystal-induced acute inflammation by retrovirally transfected prostaglandin D synthase. Arthritis Rheum 2003; 48:2931-41.
63. Fujitani Y, Kanaoka Y, Aritake K, Uodome N, Okazaki-Hatake K, Urade Y. Pronounced eosinophilic lung inflammation and Th2 cytokine release in human lipocalin-type prostaglandin D synthase transgenic mice. J Immunol 2002; 168:443-9.
64. Irikura D, Aritake K, Nagata N, Maruyama T, Shimamoto S, Urade Y. Biochemical, functional, and pharmacological characterization of AT-56, an orally active and selective inhibitor of lipocalin-type prostaglandin D synthase. J Biol Chem 2009; 284:7623-30.
65. Joo M, Kwon M, Sadikot RT et al. Induction and function of lipocalin prostaglandin D synthase in host immunity. J Immunol 2007; 179:2565-75.
66. Cipollone F, Fazia M, Iezzi A et al. Balance between PGD synthase and PGE synthase is a major determinant of atherosclerotic plaque instability in humans. Arterioscler Thromb Vasc Biol 2004; 24:1259-65.
67. Lachmann RA, Werchan S, Schachtrup C, Haitsma JJ, Spener F, Lachmann B. Liver-type fatty acid binding protein in serum and broncho-alveolar lavage in a model of acute respiratory failure because of surfactant depletion-a possible marker for lung damage? Clin Physiol Funct Imaging 2006; 26:371-5.
68. Guthmann F, Hohoff C, Fechner H et al. Expression of fatty-acid-binding proteins in cells involved in lung-specific lipid metabolism. Eur J Biochem 1998; 253:430-6.
69. Schachtrup C, Malcharek S, Haitsma JJ et al. Activation of PPARgamma reverses a defect of surfactant synthesis in mice lacking two types of fatty acid binding protein. Biochim Biophys Acta 2008; 1781:314-20.
70. Shum BO, Mackay CR, Gorgun CZ et al. The adipocyte fatty acid-binding protein aP2 is required in allergic airway inflammation. J Clin Invest 2006; 116:2183-92.
71. Ghelfi E, Karaaslan C, Berkelhamer S, Akar S, Kozakewich H, Cataltepe S. Fatty acid-binding proteins and peribronchial angiogenesis in bronchopulmonary dysplasia. Am J Respir Cell Mol Biol 2011; 45:550-6.
72. Holler J, Zakrzewicz A, Garn H et al. Increased expression of epidermal fatty acid-binding protein by alveolar macrophages during acute rejection of rat lungs. APMIS 2010; 118:791-800.
73. Wagner AJ, Stumbaugh A, Tigue Z et al. Genetic analysis of congenital cystic adenomatoid malformation reveals a novel pulmonary gene: fatty acid binding protein-7 (brain type). Pediatr Res 2008; 64:11-6.
74. Massaro GD, Massaro D. Postnatal treatment with retinoic acid increases the number of pulmonary alveoli in rats. Am J Physiol 1996; 270:L305-10.
75. Massaro D, Massaro GD. Retinoids, alveolus formation, and alveolar deficiency: clinical implications. Am J Respir Cell Mol Biol 2003; 28:271-4.
76. Plantier L, Rochette-Egly C, Goven D et al. Dysregulation of elastin expression by fibroblasts in pulmonary emphysema: role of cellular retinoic acid binding protein 2. Thorax 2008; 63:1012-7.
77. Massaro GD, Massaro D. Retinoic acid treatment partially rescues failed septation in rats and in mice. Am J Physiol Lung Cell Mol Physiol 2000; 278:L955-60.
78. Massaro GD, Massaro D. Retinoic acid treatment abrogates elastase-induced pulmonary emphysema in mice. Nat Med 1987; 3:675-7.
79. Belloni PN, Garvin L, Mao CP, Bailey-Healy I, Leaffer D. Effects of all-trans-retinoic acid in promoting alveolar repair. Chest 2000; 117:235S-241S.
80. Darlow BA, Graham PJ. Vitamin A supplementation to prevent mortality and short and long-term morbidity in very low birthweight infants. Cochrane Database Syst Rev 2011; CD000501.
81. Duggan C, Colin AA, Agil A, Higgins L, Rifai N. Vitamin A status in acute exacerbations of cystic fibrosis. Am J Clin Nutr 1996; 64:635-9.
82. Flower DR, North AC, Sansom CE. The lipocalin protein family: structural and sequence overview. Biochimica et Biophysica Acta (BBA) - Protein Structure and Molecular Enzymology 2000; 1482:9-24.